Search LXRX
LEXICON PHARMACEUTICALS, INC.
Nasdaq · CIK 1062822
Last close1.82
Daily change+0.00 (0.00%)
10 Years gain-89.90%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LXRX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
61.0Momentum
n/aAcceleration
n/aConfidence
75.0Annual Revenue17
Quarterly Revenue65
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency5.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM1,034.99%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin99.71%OK
Operating Margin-55.5%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-21.95%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $49.80M | $49.53M | -$48.91M | -$67.85M | -$67.85M | 99.45% | -98.21% | -136.24% | -105% | 363.05M |
| 2025 FY Dec 31, 2024 | n/a | $30.47M | -$197.12M | -$178.78M | -$179.81M | n/a | n/a | n/a | n/a | 320.03M |
| 2024 FY Dec 31, 2024 | $6.00M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| 2025 FY Dec 31, 2023 | n/a | $1.12M | -$171.75M | -$161.90M | -$162.37M | n/a | n/a | n/a | n/a | 221.13M |
| 2024 FY Dec 31, 2023 | $1.11M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $64.84M | sum latest 4 fiscal quarters Revenue | OK | 0001062822-26-000117, 0001062822-25-000054 |
| Revenue Growth TTM | 1,034.99% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001062822-26-000117, 0001062822-25-000054 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001062822-26-000050 |
| Revenue CAGR 5Y | 16.3% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001062822-26-000050 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001062822-26-000050 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001062822-26-000117, 0001062822-25-000054 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 99.71% | Gross Profit / Revenue | OK | 0001062822-26-000117, 0001062822-25-000054 |
| Operating Margin | -55.5% | Operating Income / Revenue | OK | 0001062822-26-000117, 0001062822-25-000054 |
| ROIC | -21.95% | NOPAT / Average Invested Capital | OK | 0001062822-26-000117, 0001062822-25-000054 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001062822-26-000117 |
| Current Ratio | 13.37x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 3.71x | (Cash + Short-term Investments) / Total Debt | OK | 0001062822-26-000117 |
| Revenue per Diluted Share | $0.15 | Revenue / Diluted Shares | OK | 0001062822-26-000117, 0001062822-25-000054 |